Filing Details
- Accession Number:
- 0001127602-22-003422
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-02-04 17:12:07
- Reporting Period:
- 2022-02-02
- Accepted Time:
- 2022-02-04 17:12:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 816956 | Conmed Corp | CNMD | Electromedical & Electrotherapeutic Apparatus (3845) | 160977505 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1261784 | Brian Concannon | C/O Conmed Corporation 11311 Concept Boulevard Largo FL 33773 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2022-02-02 | 2,027 | $135.09 | 13,400 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-02-02 | 4,200 | $136.96 | 9,200 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-02-02 | 200 | $137.91 | 9,000 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-02-02 | 2,549 | $69.03 | 11,549 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-02-02 | 2,549 | $135.08 | 9,000 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-02-02 | 2,165 | $79.94 | 11,165 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-02-02 | 2,165 | $135.08 | 9,000 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-02-02 | 1,843 | $73.94 | 10,843 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-02-02 | 1,843 | $135.06 | 9,000 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-02-02 | 1,000 | $33.43 | 10,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-02-02 | 241 | $139.03 | 9,759 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2022-02-02 | 1,000 | $39.64 | 10,759 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-02-02 | 286 | $139.03 | 10,473 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2022-02-02 | 1,000 | $55.70 | 11,473 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-02-02 | 401 | $139.03 | 11,072 | No | 4 | F | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Options To Purchase Common Stock | Disposition | 2022-02-02 | 2,549 | $0.00 | 2,549 | $69.03 |
| Common Stock | Options To Purchase Common Stock | Disposition | 2022-02-02 | 2,165 | $0.00 | 2,165 | $79.94 |
| Common Stock | Options To Purchase Common Stock | Disposition | 2022-02-02 | 1,843 | $0.00 | 1,843 | $73.94 |
| Common Stock | Sars (Stock Appreciation Rights) | Disposition | 2022-02-02 | 1,000 | $0.00 | 1,000 | $33.43 |
| Common Stock | Sars (Stock Appreciation Rights) | Disposition | 2022-02-02 | 1,000 | $0.00 | 1,000 | $39.64 |
| Common Stock | Sars (Stock Appreciation Rights) | Disposition | 2022-02-02 | 1,000 | $0.00 | 1,000 | $55.70 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2019-06-01 | 2028-06-01 | No | 4 | M | Direct |
| 0 | 2020-06-01 | 2029-06-03 | No | 4 | M | Direct |
| 0 | 2021-06-01 | 2030-06-01 | No | 4 | M | Direct |
| 0 | 2014-06-01 | 2023-07-26 | No | 4 | M | Direct |
| 0 | 2015-06-01 | 2024-09-11 | No | 4 | M | Direct |
| 0 | 2016-06-01 | 2025-06-01 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.83. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.29 to $137.06. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.88 to $137.94. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.82. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.84. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.12. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- The incentive stock options ("ISOs") were granted under the Company's 2016 Amended and Restated Non-Employee Director Equity Compensation Plan and generally vest 100% after a one year period.
- The stock options were granted under the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan and generally vest 100% after a one year period.
- The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting 100% after a one year period.
- The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting upon completion of the term of service.
Billionaire Hedge Funds
